Table 4.
Correlates of HIV disclosure at 24-month among the 122 APHIV not disclosed at inclusion, in the COHADO cohort, Abidjan (Côte d'Ivoire), Lomé (Togo), IeDEA-pWADA, 2015–2017.
| Univariate analysis | Multivariate analysis | ||||||
|---|---|---|---|---|---|---|---|
|
Total N = 122 (%) |
HIV status disclosed N = 68 (%) |
HIV status not disclosed N = 54 (%) |
P-Valuea | Full model | |||
| aOR | (95% CI) | p-value | |||||
| Sex, n (%) | 0.54 | ||||||
| Males | 58 (47.5) | 34 (50.0) | 24 (44.4) | 1.00 | — | — | |
| Females | 64 (52.5) | 34 (50.0) | 30 (55.6) | 1.02 | (0.41–2.51) | 0.96 | |
| Site, n (%) | <0.01 | ||||||
| Abidjan (Côte-d'Ivoire) | 46 (37.7) | 15 (22.1) | 31 (57.4) | 1.00 | — | — | |
| Lomé (Togo) | 76 (62.3) | 53 (77.9) | 23 (42.6) | 15.2 | (3.12–73.9) | <0.01 | |
| Orphanhood, n (%) | 0.76 | ||||||
| No | 60 (49.2) | 32 (47.1) | 28 (46.5) | ||||
| One parent | 48 (39.3) | 27 (39.7) | 21 (35.6) | ||||
| Two parents | 14 (11.5) | 9 (13.2) | 5 (17.8) | ||||
| Education level | 0.05 | ||||||
| Primary school | 66 (54.1) | 31 (45.6) | 35 (64.8) | 1.00 | — | — | |
| Middle schools | 54 (44.3) | 35 (51.5) | 19 (35.2) | 1.42 | (0.49–4.16) | 0.51 | |
| High schools | 2 (1.6) | 2 (2.9) | 0 (0.0) | 1.00 | — | — | |
| Running water access | 0.18 | ||||||
| Yes | 64 (52.4) | 32 (47.1) | 32 (59.3) | 1.00 | — | — | |
| No | 58 (47.5) | 36 (52.9) | 22 (40.7) | 0.51 | (0.11–2.12) | 0.35 | |
| Electricity access, n (%) | 0.58 | ||||||
| Yes | 119 (97.5) | 67 (98.5) | 52 (96.3) | ||||
| No | 3 (2.46) | 1 (1.5) | 2 (3.7) | ||||
| Residential environment | 0.36 | ||||||
| Urban | 110 (90.2) | 63 (92.6) | 47 (87.1) | 1.00 | — | — | |
| Rural | 12 (9.8) | 5 (7.4) | 7 (12.9) | 0.62 | (0.11–3.27) | 0.58 | |
| Living with | 0.95 | 0.93 | |||||
| Both parents | 31 (25.4) | 18 (26.5) | 13 (24.1) | 1.00 | — | — | |
| Only one parent | 55 (45.1) | 30 (44.1) | 25 (46.3) | 1.17 | (0.37–3.67) | 0.78 | |
| Other family member | 36 (29.5) | 20 (29.4) | 16 (29.6) | 0.99 | (0.27–3.61) | 0.98 | |
| WHO clinical stage, n (%) | 0.19b | ||||||
| 1, 2, 3 | 100 (81.9) | 53 (77.9) | 47 (87.1) | 1.00 | — | — | |
| 4 (AIDS) | 22 (18.1) | 15 (22.1) | 7 (12.9) | 0.44 | (0.10–1.84) | 0.26 | |
| CD4 cell count/mm3, median [IQR] | |||||||
| 546[305–843] | 508[262–850] | 548[416–843] | 0.19 c | 0.99 | (0.99–1.00) | 0.88 | |
| Virological suppression (n = 27), | |||||||
| (Viral load <50 cp/mL) | 1.00 | ||||||
| Yes | 1 (3.7) | 0 (0.0) | 1 (6.3) | ||||
| No | 26 (96.3) | 11 (100.0) | 15 (93.7) | ||||
| Age at inclusion in years, median [IQR] | |||||||
| 12[11–13] | 13[11–14] | 11[10–12] | <0.01c | 1.86 | (1.31–2.63) | <0.01 | |
| Age at ART initiation, median [IQR] | |||||||
| 6[4–9] | 8[4–11] | 5[3–7] | <0.01c | ||||
| ART duration in years, median [IQR] | |||||||
| 6[3–9] | 5[2–8] | 7[5–9] | 0.03c | 0.96 | (0.80–1.15) | 0.69 | |
a
Chi2 test;
b
Fisher's exact test;
c
Wilcoxon-Mann-Whitney test.